| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/TDE-2017-0064 |
| P8608 | Fatcat ID | release_wlgjar3cufavzji35czpqqu2gi |
| P698 | PubMed publication ID | 28944744 |
| P50 | author | David J. Brayden | Q38545212 |
| P2093 | author name string | Sarinj Fattah | |
| P2860 | cites work | Somatostatin receptor ligands in the treatment of acromegaly | Q39125449 |
| Somatostatin analogs for diagnosis and treatment of cancer | Q40624010 | ||
| Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. | Q40804196 | ||
| Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether | Q41574955 | ||
| Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2. | Q41996278 | ||
| Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations | Q42111817 | ||
| Microneedles for drug delivery via the gastrointestinal tract | Q42213867 | ||
| Differential expression of somatostatin receptor subtype 1-5 proteins in numerous human normal tissues | Q42512673 | ||
| Octreotide long-acting release (LAR): a review of its use in the management of acromegaly | Q42929208 | ||
| Therapeutic options in the management of acromegaly: focus on lanreotide Autogel | Q43078115 | ||
| SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile | Q43973971 | ||
| Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. | Q44740681 | ||
| Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. | Q44802483 | ||
| SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action | Q48897339 | ||
| Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. | Q52892914 | ||
| Oral peptide delivery by tetraether lipid liposomes. | Q55054517 | ||
| Pituitary somatostatin receptor signaling | Q24631604 | ||
| Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future | Q28070267 | ||
| Membrane transporters in drug development | Q29616802 | ||
| Epidemiology of acromegaly: review of population studies | Q30244550 | ||
| Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs | Q31105313 | ||
| Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects | Q31370470 | ||
| A novel suspension formulation enhances intestinal absorption of macromolecules via transient and reversible transport mechanisms | Q34130414 | ||
| Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone | Q34216319 | ||
| Somatostatin analogs in acromegaly | Q34727752 | ||
| P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule | Q35041828 | ||
| Permeability of porcine blood brain barrier to somatostatin analogues | Q35044168 | ||
| Octreotide long-acting release (LAR): a review of its use in the management of acromegaly | Q35580473 | ||
| Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study | Q35582894 | ||
| Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers | Q36072479 | ||
| Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly | Q36489627 | ||
| A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly | Q37162844 | ||
| Guidelines for acromegaly management: an update | Q37390174 | ||
| Inhibition of P-glycoprotein, multidrug resistance-associated protein 2 and cytochrome P450 3A4 improves the oral absorption of octreotide in rats with portal hypertension | Q37582128 | ||
| BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas | Q37633385 | ||
| Pasireotide versus octreotide in acromegaly: a head-to-head superiority study | Q37663006 | ||
| Phospholipids and lipid-based formulations in oral drug delivery | Q37735764 | ||
| Pharmacokinetic evaluation of lanreotide | Q37780553 | ||
| Somatostatin analogs: does pharmacology impact antitumor efficacy? | Q38177033 | ||
| Strategic approaches to optimizing peptide ADME properties | Q38264736 | ||
| Pasireotide in Acromegaly: A Review | Q38504642 | ||
| Pasireotide for the treatment of acromegaly | Q38710873 | ||
| Update on quality of life in patients with acromegaly | Q38978491 | ||
| Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas | Q39024218 | ||
| New medical therapies on the horizon: oral octreotide | Q39090289 | ||
| Archaeal lipids in oral delivery of therapeutic peptides. | Q39096991 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 867-878 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | Therapeutic delivery | Q26842827 |
| P1476 | title | Progress in the formulation and delivery of somatostatin analogs for acromegaly | |
| P478 | volume | 8 |
Search more.